Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff AS, Fraaij PL, Ndagijimana J, Verweel G, Hartwig NG, Niehues T, De Groot R, Burger DM.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-8.

PMID:
15851915
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.
4.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
5.

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.

Hill A, van der Lugt J, Sawyer W, Boffito M.

AIDS. 2009 Nov 13;23(17):2237-45. doi: 10.1097/QAD.0b013e328332c3a5. Review. Erratum in: AIDS. 2010 Mar 27;24(6):940.

PMID:
19809270
6.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Oldfield V, Plosker GL.

Drugs. 2006;66(9):1275-99. Review.

PMID:
16827606
7.

Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.

Kaplan SS, Hicks CB.

Expert Opin Pharmacother. 2005 Aug;6(9):1573-85. Review.

PMID:
16086645
8.

Lopinavir/ritonavir: appraisal of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2007 Apr;43(4):221-47. Review.

PMID:
17460785
9.

Efavirenz for HIV-1 infection in adults: an overview.

Fortin C, Joly V.

Expert Rev Anti Infect Ther. 2004 Oct;2(5):671-84. Review.

PMID:
15482231
10.
11.

Clinical history of efavirenz.

Ruiz N.

Int J Clin Pract Suppl. 1999 Jun;103:3-7. Review.

PMID:
10622035
12.

Lopinavir/ritonavir.

Porche DJ.

J Assoc Nurses AIDS Care. 2001 Mar-Apr;12(2):101-4. Review.

PMID:
11296724
13.

Kaletra (lopinavir/ritonavir).

Corbett AH, Lim ML, Kashuba AD.

Ann Pharmacother. 2002 Jul-Aug;36(7-8):1193-203. Review.

PMID:
12086554
14.

Dose-ranging studies.

Manion D.

Int J Clin Pract Suppl. 1999 Jun;103:8-9. Review.

PMID:
10622036
15.

Paediatric treatment issues.

Walters S.

Int J Clin Pract Suppl. 1999 Jun;103:26-9. Review.

PMID:
10622040
16.

Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.

Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, Okulicz JF, Clifford DB, Hachad H, Levy RH; Quality Standards Subcommittee Of The American Academy Of Neurology; Ad Hoc Task Force Of The Commission On Therapeutic Strategies Of The International League Against Epilepsy.

Epilepsia. 2012 Jan;53(1):207-14. doi: 10.1111/j.1528-1167.2011.03335.x. Review.

17.

Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management.

Saberi P, Phengrasamy T, Nguyen DP.

HIV Med. 2013 Oct;14(9):519-29. doi: 10.1111/hiv.12039. Epub 2013 Apr 16. Review.

18.

What's new: newly approved drugs for children.

Abbott MB, Levin RH.

Pediatr Rev. 2001 Oct;22(10):357-9. Review. No abstract available. Erratum in: Pediatr Rev 2002 Mar;23(3) following 106.

PMID:
11581490

Supplemental Content

Support Center